Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
18.03.2022 - CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) - Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic .
Leading BioSciences Closes Merger with Seneca Biopharma; Begins Trading on Nasdaq
Leading BioSciences, Inc. a Carlsbad, CA-based late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, closed its previously announced merger transaction with Seneca Biopharma, Inc.
The combined, publicly traded company will operate under the name Palisade Bio, Inc., and its common stock is expected to commence trading on the Nasdaq Capital Market on April 28, 2021, under the ticker symbol “PALI.”
In addition, the company has announced the closing of the previously announced private placement led by Altium Capital that included $20.0 million in cash plus the cancelation of outstanding principal and interest pursuant to the notes previously issued to the investor.